CTHRC1 is associated with immune cell infiltration and functions as an adverse marker for prognosis in head and neck squamous cell carcinoma

RUOLEI ZHONG[1*], MENGLING YANG[2*], RUI ZHU[2], JIAHUA ZHANG[3] and LI WANG[4]

[1]Department of Hepatobiliary Surgery, Affiliated Hospital of Jianghan University, Wuhan, Hubei 430015;
[2]Department of Integrated Traditional Chinese and Western Medicine, [3]Center for Stem Cell Research and Application and [4]Department of Emergency Surgery, Union Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China

Abstract. Collagen triple helix repeat containing 1 (CTHRC1) is a secreted glycoprotein that decreases the deposition of collagen matrix and accelerates tumor metastasis. However, the relationship between CTHRC1 and the outcomes of head and neck squamous cell carcinoma (HNSCC) and tumor-infiltrating lymphocytes remains unclear. In the present study, the transcriptional level of CTHRC1 and its association with overall survival (OS) and relapse-free survival (RFS) time in diverse cancer types were evaluated using The Cancer Genome Atlas, Tumor Immune Estimation Resource (TIMER), ONCOMINE and Kaplan-Meier plotter databases. The association of CTHRC1 expression level with the clinicopathological parameters of patients with HNSCC from The University of ALabama at Birmingham CANcer data analysis Portal (UALCAN) database were also evaluated. Enrichment analysis of CTHRC1 was carried out using gene set enrichment analysis software. CIBERSORT and TIMER databases were used to evaluate the relationship between the expression level of CTHRC1 and the proportion of tumor-infiltrating immune cells (TICs) in multiple cancer types. Moreover, immunohistochemistry was used to verify the expression of CTHRC1 in clinical samples of HNSCC. CTHRC1 was upregulated in HNSCC and high expression of CTHRC1 was associated with worsening clinicopathologic parameters and shorter OS and RFS times. There were eight HALLMARK gene sets, 1,231 immune signature gene sets and 14 KEGG gene sets significantly enriched in the high CTHRC1 expression group, while no gene set was enriched in the low CTHRC1 expression group. The expression of CTHRC1 was closely correlated with the proportion of TICs, where the expression of CTHRC1 was significantly positively correlated with the amount of infiltrated M0 and M2 macrophages, and significantly negatively associated with the levels of M1 macrophages. These findings suggest that CTHRC1 is an adverse prognostic marker and is associated with immune cell infiltration in HNSCC.

Introduction

Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignant tumors, accounting for ~90% of the total number of head and neck tumors (1), with >800,000 new cases globally every year (2). Multiple therapies, including surgery, radiotherapy, chemotherapy and systemic therapy, can be applied for HNSCC treatment (3); however, the 5-year survival rate is only 50% (4). HNSCC is an immunosuppressive disease which demonstrates impaired function of immune cells (5-7). The mechanisms of immune escape in HNSCC include upregulation of programmed death-ligand 1 in human papillomavirus (HPV)-positive tumors, downregulation of interferon regulatory factors and activation of the STAT1 signaling pathway (3), which contribute to the development of HNSCC. Previous studies have reported that Keytruda® and Opdivo® can efficiently prevent the immune escape state and improve the prognosis of patients due to their specific binding to PD-1 (8,9). Therefore, it is important to explore immune checkpoints in the development of targeted drugs to improve the prognosis of patients with HNSCC.

Collagen triple helix repeat containing 1 (CTHRC1) was first discovered in the injured arteries of rats (10). CTHRC1 serves an important role in wound repair (11), hepatocyte fibrosis (12), bone reconstruction (13) and adipose tissue formation (14). In

Correspondence to: Dr Jiahua Zhang, Center for Stem Cell Research and Application, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei 430022, P.R. China
E-mail: zhangjh@hust.edu.cn

Dr Li Wang, Department of Emergency Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei 430022, P.R. China
E-mail: wangli1229@hust.edu.cn

*Contributed equally

previous studies, CTHRC1 has been reported to be abnormally expressed in colorectal and gastric cancer (15-17). Furthermore, CTHRC1 inhibits collagen deposition by mediating the Wnt/planar cell polarity (PCP), TGF-β/bone morphogenetic protein and ERK signaling pathways, and participates in the metastasis of tumors (18-20). CTHRC1 promotes the proliferation of HeLa cells via activation of the Wnt/PCP signaling pathway and promotion of the proliferation of breast cancer cells via a Linc00707-mediated competing endogenous RNA mechanism (21,22). Furthermore, upregulation of CTHRC1 results in a worse prognosis for patients with liver and epithelial ovarian cancers (19,23). Therefore, CTHRC1 can be considered a carcinogenic driving factor for the progression and metastasis of esophageal squamous cell carcinoma, and as a potential biomarker for prognosis and individualized treatment (20,24). It has been reported that CTHRC1 is involved in immune cell infiltration in the tumor microenvironment, has a pivotal role in the regulation of M2 macrophage polarization in ovarian tumors and is seen as a target for antitumor immunotherapy (25). However, the roles of CTHRC1 in HNSCC and its tumor immune microenvironment remain unclear. Therefore, in the present study, the Tumor Immune Estimation Resource (TIMER) and ONCOMINE databases were used to analyze the transcriptional levels of CTHRC1 in HNSCC. The University of ALabama at Birmingham CANcer data analysis Portal (UALCAN) and CIBERSORT websites were used to evaluate the association between CTHRC1 expression levels and clinical features or the immune microenvironment, to provide solid evidence for the significance of CTHRC1 in HNSCC.

Materials and methods

The cancer genome atlas (TCGA) database analysis. The RNA-seq data (workflow type, HTSeq-FPKM) and relevant clinical data for the 'TCGA-HNSC' cohort, including 502 tumor samples and 44 normal samples, were downloaded from the TCGA database (https://tcga-data.nci.nih.gov/tcga/) (26).

ONCOMINE database analysis. Expression levels of CTHRC1 were analyzed in multiple cancer types using the ONCOMINE database (https://www.oncomine.org/resource/main.html) (27), and the cut-off P-value used was 0.05, while the log fold change cut-off was equal to 1.

TIMER database analysis. The TIMER database (https://cistrome.shinyapps.io/timer/) (28) has incorporated 39 types of cancer in the TCGA database. Gene expression levels were presented as log2 transcripts per million. The TIMER database was used to evaluate the transcriptional level of CTHRC1 in multiple cancer types and its correlation with immune cell infiltration.

Kaplan-Meier (KM) plotter analysis. KM plotter contains data and clinical information from the Gene Expression Omnibus, TCGA and European Genome-Phenome Archive databases. The prognostic value of the mRNA expression levels of CTHRC1 in 21 cancer types was evaluated using the KM plotter (http://kmplot.com/analysis/). P<0.05 was considered to indicate a statistically significant difference.

UALCAN analysis. UALCAN (http://ualcan.path.uab.edu) (29) contains level 3 RNA-seq data and clinical information from 31 cancer types from the TCGA database and is an interactive and comprehensive web resource for analyzing cancer omics data. In the present study, UALCAN was used to investigate the relationship between the levels of CTHRC1 and clinicopathologic parameters, including age, TP53 mutation, nodal metastasis (N0, no regional lymph node metastasis; N1, metastases in 1-3 axillary lymph nodes; N2, metastases in 4-9 axillary lymph nodes; N3, metastases in ≥10 axillary lymph nodes), individual cancer stages, tumor grades (grade 1, well differentiated; grade 2, moderately grade; grade 3, poorly differentiated; grade 4, undifferentiated) (30,31) and HPV status. Unpaired student's t-test was used to assess transcriptional expression and P<0.05 was considered to indicate a statistically significant difference.

Tumor infiltration cell (TIC) profile analysis. Based on the validated leukocyte gene signature matrix (LM22), the CIBERSORT (http://cibersort.stanford.edu/) computational method was used to analyze the infiltration ratio of 22 TICs in each HNSCC sample, and the ratios of all were equal to 1.

Barplot, corrplot, vioplot, Venn and scatter plot. R 64.4.0.0 software (https://www.r-project.org) was used to plot associations with TICs. The Barplot and corrplot were generated using the corrplot package (version 0.84, http://cran.r-project.org/src/contrib/Archive/corrplot/), while vioplot was produced using the BiocManager (version 3.12, http://www.bioconductor.org/install) and vioplot packages (version 0.3.4, http://cran.r-project.org/src/contrib/Archive/vioplot/). The Venn plot was generated using the VennDiagram package (http://www.rdocumentation.org/packages/VennDiagram/versions/1.6.18). The scatter plot was generated using the ggplot2 (version 3.2.1, http://cran.r-project.org/src/contrib/Archive/ggplot2/), ggpubr (version 0.2.4, http://cran.r-project.org/src/contrib/Archive/ggpubr/) and ggExtra packages (version 0.9, http://cran.r-project.org/src/contrib/Archive/ggExtra/). All packages were used with standard settings.

Gene sets for enrichment analysis (GSEA). GSEA were downloaded from the Broad Institute Website (version 4.0.2, http://software.broadinstitute.org/gsea/index.jsp). HALLMARK, Kyoto Encyclopedia of Genes and Genomes (KEGG) and IMMUNE SIGNATURE gene sets were obtained from the Molecular Signatures Database (http://www.gsea-msigdb.org/gsea/msigdb/index.jsp). The transcriptome of patients with HNSCC were assessed using GSEA software (version 4.0.2, http://software.broadinstitute.org/gsea/downloads.jsp) and all the samples with nominal (NOM) P<0.01 and false discovery rate (FDR) Q<0.06 were considered to indicate a statistically significant difference.

Tissue microarray (TMA) and ethical approval. From January 2020 to December 2020, 70 patients with primary HNSCC who underwent radical resection of tumors, did not receive preoperative radiotherapy or chemotherapy in the People's Hospital of Tongxu County (Kaifeng, China) and provided written informed consent were enrolled in the present study, and their tumor tissue samples were collected. A total of

11 patients with benign head and neck lesions were included, informed consent was signed and normal tissue samples adjacent to benign lesions were collected. Patients with HNSCC were between 32 and 79 years old, with a mean age of 59.9 years. Human tissue specimens were obtained from patients who had provided written informed consent and the present study and tissue collection were approved by the Ethics Supervision Committee of The People's Hospital of Tongxu County (Kaifeng, China; approval no. TX20NP003) and the National Human Genetic Resources Sharing Service Platform (2005DKA21300). The study protocol was approved by the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China; approval no. 2020IEC-J050).

Immunohistochemistry (IHC). The tissue samples were fixed using 10% formalin solution at room temperature for 24 h, dehydrated, embedded in paraffin and sectioned into 4 μm sections. The expression of CTHRC1 protein was assessed using the immunohistochemistry ultrasensitive TMS-P method. After the sections were deparaffinized, hydrated and washed, they were placed in EDTA repair solution (pH 9.0), and boiled using a microwave oven for 2 min, and then cooled to room temperature naturally. Then sections were blocked using 3% H_2O_2 solution for 15 min at room temperature in the dark room. The sections were washed and incubated overnight at 4˚C with CTHRC1 antibodies (1:200; cat no. 16534-1-AP; Wuhan Sanying Biotechnology). After washing three times with phosphate buffered saline, the sections were stained with secondary antibodies using the Ready-to-use Ultrasensitive™ SP kit (cat. no. Kit-9720; Fuzhou Maxin Biotechnology Development Co., Ltd.) and incubated for 30 min in a wet box at 37˚C. DAB horseradish peroxidase color development kit (cat no. P0202; Beyotime Institute of Biotechnology) was used for color development. The sections were re-stained using hematoxylin staining solution (cat no. C0107; Beyotime Institute of Biotechnology) for 2 min at room temperature, dehydrated using ethanol, sealed and imaged using a Pannoramic MIDI scanner (3DHISTECH, Ltd.) and ImageJ software (version 1.8.0, National Institutes of Health) was used for image analysis. The cells on the microarrays were scored according to the staining intensity of the marker, as follows: 0, no coloring; 1, light yellow; 2, brown-yellow; and 3, tan. The proportion of cells under each score was then recorded, and the H-score value of each specimen was calculated. H-scores were defined as: (1x percentage of cells staining at 1) + (2x percentage of cells staining at 2) + (3x percentage of cells staining at 3).

Statistical analysis. SPSS 26.0 software (IBM Corp.) was used for statistical analyses. Fisher's exact test was used to analyze the relationship between clinical characteristics and CTHRC1 mRNA expression levels. The Mann-Whitney U test was used for calculating statistical differences in the H-scores in TMA and the ratio differentiation level of 21 types of immune cells in high and low CTHRC1 expression groups in HNSCC. Pearson correlation coefficient analysis was used to assess the correlation value between two kinds of cells. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

CTHRC1 was upregulated in multiple human cancer types. To evaluate the distinct prognostic and potential therapeutic value of CTHRC1 in HNSCC, the mRNA expression level of CTHRC1 was studied using the TCGA, ONCOMINE and TIMER databases. Data from the TCGA database showed that CTHRC1 was highly expressed in 16 cancer types, including HNSCC (Fig. 1A and B). Results from the ONCOMINE database also showed that the mRNA expression levels of CTHRC1 were significantly upregulated in multiple tumor tissues compared with normal tissues (Fig. 1C). Furthermore, the same result was demonstrated by HNSCC clinical tissues samples when compared with normal tissues (Fig. 1D and E). Taken together, these data indicated that CTHRC1 was enriched in multiple human cancer types.

Association of CTHRC1 expression with clinicopathological parameters of patients with HNSCC. Since clinical pathology can determine the progression and prognosis of diseases, the association of transcriptional levels of CTHRC1 with clinicopathological parameters in patients with HNSCC was investigated using UALCAN. As presented in Fig. 2 and Table I, the transcriptional level of CTHRC1 was significantly associated with age (Fig. 2A), TP53 mutation (Fig. 2B), HPV status (Fig. 2C), tumor grade (Fig. 2D), nodal metastasis status (Fig. 2E) and individual cancer stages (Fig. 2F). The mRNA expression level of CTHRC1 increased markedly with age. Patients with TP53 mutations and those who were HPV-negative also had higher CTHRC1 mRNA expression levels. CTHRC1 mRNA expression levels increased with tumor progression and, in general, the more lymph node metastases in patients, the higher the mRNA expression level of CTHRC1. Among the patients, the transcriptional level of CTHRC1 in the N2 group (4-9 axillary lymph node metastasis) was lower than that of the N3 group (≥10 axillary lymph node metastasis), which may be due to the limited sample size. Additionally, the mRNA expression level of CTHRC1 in pathological stage IV patients was significantly higher than those in stage III or II, but markedly lower than that in patients with stage I, which may also be due to the difference in sample size. In summary, these results suggested that the mRNA expression level of CTHRC1 was closely related to the clinicopathological parameters of patients with HNSCC.

Potential value of CTHRC1 mRNA expression level in assessment of the survival time of patients with HNSCC. Since CTHRC1 was differentially expressed in diverse cancer types, the relationship between CTHRC1 expression levels and the survival time of patients with HNSCC was next evaluated using the KM plotter. Patients were grouped, into CTHRC1 high and CTHRC1 low expression groups, using the auto select best cutoff function on the KM plotter website (32). The data indicated that the CTHRC1 high expression group had a worse OS (Fig. 3A) and RFS time (Fig. 3B). These results demonstrated that CTHRC1 had the potential to be a prognostic biomarker in HNSCC.

CTHRC1 has a potential role in mediating tumor progression. In order to further investigate the potential function of CTHRC1, GSEA of the data from patients with HNSCC was

Figure 1. CTHRC1 expression levels in different types of human cancer. (A) The transcription levels of human CTHRC1 in different tumor types in the TCGA database were assessed using TIMER. (B) CTHRC1 transcriptional levels in adjacent and tumor tissues in patients with HNSCC from the TCGA database. (C) Expression level of CTHRC1 in different cancer datasets compared with normal tissues in the ONCOMINE database, the number indicated the number of data sets included by The National Center for Biotechnology Information that matched the conditions. (D) Scatter plot of CTHRC1 expression (using H-score) in HNSCC tissues compared with normal tissues. (E) Representative immunohistochemistry of CTHRC1 in clinical specimens. *P<0.05, **P<0.01, ***P<0.001. TCGA, The Cancer Genome Atlas; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangio carcinoma; CNS, central nervous system; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; HPV, human papillomavirus; neg, negative; pos, positive; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, (brain) lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumor; THCA, thyroid carcinoma; THYM, thymoma, UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma; CTHRC1, collagen triple helix repeat containing 1; TPM, transcripts per million.

Table I. Relationship between clinical characteristics and CTHRC1 expression in patients with head and neck squamous cell carcinoma.

Characteristic	Low expression of CTHRC1, n=251 (%)	High expression of CTHRC1, n=250 (%)	P-value
Sex, n			0.978
Female	67 (26.7)	67 (26.8)	
Male	184 (73.3)	183 (73.2)	
Age, n			0.072
<60 years	121 (48.4)	100 (40.0)	
≥60 years	129 (51.6)	150 (60.0)	
HPV status, n			0.009
Negative	196 (81.3)	216 (90.0)	
Positive	45 (18.7)	24 (10.0)	
Tumor stage, n			0.118
1	20 (9.0)	26 (11.7)	
2	73 (32.7)	59 (26.6)	
3	54 (24.2)	42 (18.9)	
4	76 (34.1)	95 (42.8)	
Node stage, n			0.412
0	93 (45.8)	78 (38.0)	
1	32 (15.8)	33 (16.1)	
2	75 (36.9)	90 (43.9)	
3	3 (1.5)	4 (2.0)	
Metastasis stage, n			>0.999
0	97 (99.0)	89 (100.0)	
1	1 (1.0)	0 (0)	
Pathological Stage, n			0.070
I	10 (4.6)	15 (6.9)	
II	44 (20.4)	26 (12.0)	
III	41 (19.0)	37 (17.1)	
IV	121 (56.0)	139 (64.1)	
Grade, n			0.016
1	39 (16.2)	22 (9.1)	
2	150 (62.2)	150 (62.2)	
3	50 (20.7)	69 (28.6)	
4	2 (0.8)	0 (0)	
Radiation therapy, n			0.985
No	77 (34.8)	73 (34.9)	
Yes	144 (65.2)	136 (65.1)	

A total of 501 patients were included, including 251 patients in the low expression group and 250 patients in the high expression group, certain patients had incomplete clinical information available. In each characteristic, patients lacking that information were excluded. CTHRC1, collagen triple helix repeat containing 1; HPV, human papillomavirus.

conducted. A total of eight HALLMARK gene sets (Fig. 4A), 14 KEGG gene sets (Fig. 4B) and 1,231 immune signature gene sets (Fig. 4C) were significantly enriched in the high CTHRC1 expression groups (NOM P<0.01; FDR Q<0.06). These gene sets included angiogenesis, apical junction, coagulation, epithelial mesenchymal transformation (EMT), the KRAS signaling pathway, the notch signaling pathway, glycosaminoglycan biosynthesis, chondroitin sulfate and the TGF-β signaling pathway. Most of these gene sets serve pivotal roles in tumorigenesis. Therefore, CTHRC1 may mediate immune cell infiltration during cancer development, and it may be regarded as an important indicator for cancer progression.

Association of CTHRC1 with immune cell infiltration in HNSCC. The immune system serves pivotal roles in the tumorigenesis of HNSCC (3). The aforementioned data showed that CTHRC1 may be involved in immune responses and tumor associated pathways. Therefore, the association between CTHRC1 expression and immune cell invasion in patients with HNSCC from the TIMER database was evaluated (Fig. 5A). The results indicated that CTHRC1 expression was significantly correlated with the degree of infiltration of B cells, CD4+ T cells, neutrophils and dendritic cells (DCs) in HPV negative patients with HNSCC (Fig. 5B). However, no significant correlation was demonstrated for these groups in HPV positive patients with HNSCC. The expression of CTHRC1 was significantly associated with the infiltration of macrophages in both HPV negative and positive patients with HNSCC (Fig. 5C). This suggested that the relationship between CTHRC1 expression and macrophage infiltration was not related to HPV infection. Collectively, these results demonstrated that CTHRC1 expression was significantly associated with immune cell infiltration in HNSCC.

The correlation of CTHRC1 expression with the proportion and distribution of TICs in HNSCC. The infiltration of 22 TICs in each HNSCC sample and the CIBERSORT algorithm was used to further evaluate the correlation between the transcriptional levels of CTHRC1 and the immune microenvironment (Fig. 6A and B). Correlation analysis indicated that the transcriptional levels of CTHRC1 were significantly positively correlated with M0 macrophages (P=2.1x10^{-13}; Fig. 7A), M2 macrophages (P=6.7x10^{-5}; Fig. 7B) and resting CD4+ memory T cells (P=5.2x10^{-4}; Fig. 7C), and were significantly negatively associated with the levels of activated CD4+ memory T cells (P=3.8x10^{-10}; Fig. 7D), M1 macrophages (P=2.6x10^{-4}; Fig. 7E), activated natural killer (NK) cells (P=2.1x10^{-4}; Fig. 7F), monocytes (P=2.1x10^{-2}; Fig. 7G), CD8+ T cells (P=5.9x10^{-9}; Fig. 7H), activated DCs (P=4.2x10^{-5}; Fig. 7I) and follicular helper T (Tfh) cells (P=3.0x10^{-3}; Fig. 7J) (Table II). Analysis demonstrated that the transcriptional levels of CTHRC1 were correlated with the infiltration of 10 types of TICs, including resting CD4+ memory T cells, memory B cells, activated CD4+ memory T cells, CD8+ T cells, Tfh cells, M0 macrophages, activated NK cells, M1 macrophages, M2 macrophages and activated DCs (Fig. 7K and L). The high CTHRC1 expression group tended to have a larger proportion of resting CD4+ memory T cells, M0 macrophages and M2 macrophages

Figure 2. Relationship between mRNA expression levels of CTHRC1 and the clinical characteristics of patients with HNSCC. Relationship between CTHRC1 mRNA expression level and (A) age, (B) TP53 mutation, (C) HPV status, (D) tumor grade, (E) nodal metastasis status and (F) cancer stages in HNSCC patients. *P<0.05, **P<0.01, ***P<0.001. CTHRC1, collagen triple helix repeat containing 1; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; TCGA, The Cancer Genome Atlas; Yrs, years.


Figure 3. KM survival analysis of CTHRC1 in head and neck squamous cell carcinoma from the KM Plotter database. (A) Overall survival and (B) relapse-free survival. CTHRC1, collagen triple helix repeat containing 1; HR, hazard ratio; KM, Kaplan-Meier.

compared with the low CTHRC1 expression group, whereas the low CTHRC1 expression group had a larger proportion of resting CD4+ memory T cells, memory B cells, activated CD4+ memory T cells, CD8+ T cells, Tfh cells, activated NK cells, M1 macrophages and activated DCs compared with the high CTHRC1 expression group.

Discussion

HNSCC is among the six most common types of human tumor. Despite the development of medical technology the survival rate of patients with HNSCC is still low (33). Abnormal gene expression or mutations may be closely related to the

Figure 4. Gene sets for enrichment analysis for patients with head and neck squamous cell carcinoma with high or low CTHRC1 expression. Each row represents a specific set of genes with a unique color. Enriched gene sets with high expression of CTHRC1 in (A) HALLMARK, (B) KEGG and (C) IMMUNE SIGNITURE. Representative gene sets are shown. Nominal P<0.01, false discovery rate Q<0.06. CTHRC1, collagen triple helix repeat containing 1; KEGG, Kyoto Encyclopedia of Genes and Genomes.

occurrence, development and prognosis of tumors. However, the molecular mechanisms of HNSCC still need to be investigated. In the present study, it was found that CTHRC1 was

abnormally upregulated in HNSCC and was significantly associated with age, TP53 mutation, nodal metastasis status, individual cancer stages and HPV status. Furthermore, high

Figure 5. Correlation between tumor-infiltrating immune cell proportions and CTHRC1 expression in HNSCC in the Tumor Immune Estimation Resource database. (A) HNSCC, (B) HPVneg HNSCC and (C) HPVpos HNSCC. CTHRC1, collagen triple helix repeat containing 1; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; neg, negative; pos, positive.

Figure 6. TIC profiles and correlation analysis of HNSCC samples. (A) The proportion of 22 types of TICs in HNSCC tumor samples. (B) Heatmap showing the correlation between 22 kinds of TICs, the number in each box indicates the corresponding correlation value between two kinds of cells. CTHRC1, collagen triple helix repeat containing 1; HNSCC, with head and neck squamous cell carcinoma; TICs, tumor-infiltrating immune cells.

Figure 7. Association between the percentage of each TIC and the CTHRC1 expression level. (A-J) The association of the percentage of 10 types of TICs with the transcriptional levels of CTHRC1. The linear model of immune cell proportional tendency and CTHRC1 expression was fitted by the gray line, and Pearson coefficient was used to test the correlation. (K) Violin plot indicating the ratio differentiation level of 21 types of immune cells in high and low CTHRC1 expression groups in head and neck squamous cell carcinoma tumor samples. (L) Venn plot displaying 10 kinds of TICs correlated with CTHRC1 expression codetermined by difference and correlation tests displayed in violin and scatter plots, respectively. CTHRC1, collagen triple helix repeat containing 1; NK, natural killer; TICs, tumor-infiltrating immune cells.

expression levels of CTHRC1 were significantly associated with shorter OS and RFS times in patients with HNSCC. These results demonstrated that CTHRC1 may function as a pro-oncogene in HNSCC.

CTHRC1 is a secretory glycoprotein which negatively regulates the deposition of collagen matrix and is involved in vascular remodeling and cell migration (10). In previous studies, the mRNA and protein expression levels of CTHRC1

Table II. Correlation analysis between collagen triple helix repeat containing 1 and related gene markers of tumor-infiltrating immune cells in Tumor Immune Estimation Resource.

Cell type	Gene marker	None[a]		Purity[b]	
		Cor[c]	P-value	Cor	P-value
CD8+ T cell	CD8A	-0.005	9.19×10^{-1}	-0.277	4.03×10^{-10}
	CD8B	0.048	2.90×10^{-1}	-0.242	5.06×10^{-8}
T cell (general)	CD3D	0.029	5.22×10^{-1}	-0.298	1.35×10^{-11}
	CD3E	0.110	1.49×10^{-2}	-0.299	1.17×10^{-11}
	CD2	0.116	9.77×10^{-3}	-0.285	1.15×10^{-10}
B cell	CD19	0.028	5.36×10^{-1}	-0.261	4.33×10^{-9}
	CD79A	0.053	2.43×10^{-1}	-0.228	3.05×10^{-7}
Monocyte	CD86	0.358	2.55×10^{-16}	-0.295	2.26×10^{-11}
	CSF1R	0.415	5.94×10^{-22}	-0.304	4.98×10^{-12}
TAM	CCL2	0.394	1.07×10^{-19}	-0.258	5.98×10^{-9}
	CD68	0.272	9.12×10^{-10}	-0.172	1.24×10^{-4}
	IL10	0.332	4.03×10^{-14}	-0.313	1.21×10^{-12}
M1 Macrophage	NOS2	0.122	6.55×10^{-3}	0.071	1.16×10^{-1}
	IRF5	0.103	2.26×10^{-2}	-0.001	9.75×10^{-1}
	PTGS2	-0.006	8.96×10^{-1}	0.1	2.67×10^{-2}
M2 Macrophage	CD163	0.399	3.28×10^{-20}	-0.286	1.02×10^{-10}
	VSIG4	0.425	5.06×10^{-23}	-0.257	7.42×10^{-9}
	MS4A4A	0.438	1.69×10^{-24}	-0.287	8.35×10^{-11}
Neutrophils	CEACAM8	0.001	9.90×10^{-1}	0.034	4.48×10^{-1}
	ITGAM	0.416	5.06×10^{-23}	-0.137	2.27×10^{-3}
	CCR7	0.194	1.53×10^{-5}	-0.322	2.23×10^{-13}
Natural killer cell	KIR2DL1	-0.006	8.93×10^{-1}	-0.093	3.81×10^{-2}
	KIR2DL3	-0.01	8.20×10^{-1}	-0.136	2.56×10^{-3}
	KIR2DL4	-0.134	2.89×10^{-3}	-0.183	4.30×10^{-5}
	KIR3DL1	-0.042	3.48×10^{-1}	-0.144	1.35×10^{-3}
	KIR3DL2	0.047	2.97×10^{-1}	-0.147	1.05×10^{-3}
	KIR3DL3	-0.045	3.23×10^{-1}	-0.086	5.68×10^{-2}
	KIR2DS4	0.017	7.12×10^{-1}	-0.148	9.93×10^{-4}
Dendritic cell	HLA-DPB1	0.223	6.05×10^{-7}	-0.302	7.78×10^{-12}
	HLA-DQB1	0.178	7.19×10^{-5}	-0.228	3.28×10^{-7}
	HLA-DRA	0.194	1.41×10^{-5}	-0.299	1.16×10^{-11}
	HLA-DPA1	-0.209	7.58×10^{-2}	-0.52	2.00×10^{-6}
	BDCA-1 (CD1C)	-0.01	9.34×10^{-1}	-0.58	5.92×10^{-8}
	BDCA-4 (NRP1)	0.455	5.15×10^{-5}	0.065	5.80×10^{-1}
	CD11c (ITGAX)	-0.064	5.88×10^{-1}	-0.387	6.55×10^{-4}
Th1	T-bet (TBX21)	0.166	1.59×10^{-1}	-0.617	4.68×10^{-9}
	STAT4	0.133	2.64×10^{-1}	-0.496	7.06×10^{-6}
	STAT1	0.291	1.26×10^{-2}	0.05	6.69×10^{-1}
	IFN-γ (IFNG)	0.092	4.37×10^{-1}	-0.421	1.85×10^{-4}
	TNF-α (TNF)	0.112	1.03×10^{-1}	-0.467	2.7×10^{-5}
Th2	GATA3	0.248	2.63×10^{-8}	-0.227	3.63×10^{-7}
	STAT6	0.056	2.12×10^{-1}	0.069	1.26×10^{-1}
	STAT5A	0.188	2.81×10^{-5}	-0.132	3.28×10^{-3}
	IL13	0.071	1.15×10^{-1}	-0.154	5.78×10^{-4}
Tfh	BCL6	0.192	1.03×10^{-1}	0.25	3.19×10^{-2}
	IL21	NA	NA	NA	NA
Th17	STAT3	0.124	2.96×10^{-1}	0.062	5.98×10^{-1}
	IL17A	0.236	4.42×10^{-2}	-0.238	4.09×10^{-2}

Table II. Continued.

Cell type	Gene marker	None[a]		Purity[b]	
		Cor[c]	P-value	Cor	P-value
Treg	FOXP3	0.312	7.25×10^{-3}	0.009	9.37×10^{-1}
	CCR8	0.129	2.77×10^{-1}	-0.33	4.11×10^{-3}
	STAT5B	0.008	9.44×10^{-1}	-0.036	7.59×10^{-1}
	TGFβ (TGFB1)	0.49	1.08×10^{-5}	-0.263	2.35×10^{-2}
T cell exhaustion	PD-1 (PDCD1)	0.109	3.58×10^{-1}	-0.581	5.89×10^{-8}
	CTLA4	0.206	8.04×10^{-2}	-0.504	4.78×10^{-6}
	LAG3	0.195	9.89×10^{-2}	-0.259	2.61×10^{-2}
	TIM-3 (HAVCR2)	-0.001	9.94×10^{-1}	-0.552	3.34×10^{-7}
	GZMB	0.062	6.05×10^{-1}	-0.406	3.33×10^{-4}

[a]None, correlation without adjustment. [b]Purity, correlation adjusted by purity. [c]Cor, R value of Spearman's correlation. TAM, tumor-associated macrophage; Th, T helper cell; Tfh, follicular helper T cell; Treg, regulatory T cell; NA, not available in database.

in oral squamous cell carcinoma samples were found to be higher than those in normal specimens (34), and were associated with metastasis in tongue squamous cell carcinoma (35). Therefore, it could be hypothesized that CTHRC1 may be involved in the development of head and neck tumors.

In the present study, analysis indicated that upregulation of CTHRC1 was mainly involved in tumor and immune-related pathways, such as angiogenesis, apical junction, EMT and the KRAS and TGF-β signaling pathways. The EMT signaling pathway is associated with visibility, acquisition of mobility and self-renewal (36). The abnormal activation of the KRAS (37), notch (38) and TGF-β (39) signaling pathways are closely related to tumorigenesis. In the present study, upregulation of CTHRC1 was indicated in 1,231 immune related pathways, which suggested a potential regulatory role of CTHRC1 in the tumor immune microenvironment. Furthermore, the results also showed that CTHRC1 was significantly positively associated with M0 macrophages, M2 macrophages and resting CD4+ memory T cells, and significantly negatively associated with the levels of activated CD4+ memory T cells, activated NK cells, M1 macrophages, CD8+ T cells, monocytes, activated DCs and Tfh cells. Moreover, the high CTHRC1 expression group tended to have a larger proportion of M0 macrophages and M2 macrophages compared with the low CTHRC1 expression group, while the low CTHRC1 expression group had a larger proportion of M1 macrophages compared with the high CTHRC1 expression group. A previous study reported that CTHRC1 can activate the STAT6 signaling pathway, induce the M2-like macrophage phenotype in a dose-dependent manner, and improve the migration and invasion ability of ovarian cancer cells (40). Therefore, CTHRC1 may mediate the occurrence and development of HNSCC by mediating macrophage polarization, which leads to poor prognosis.

There are several limitations and challenges in the present study. Firstly, the sample size is small. Larger studies in HNSCC are needed to confirm the results. Secondly, CTHRC1 expression may not be a highly specific diagnostic and prognostic biomarker of HNSCC in humans, but be a shared diagnostic and prognostic biomarker of survival in different human cancers (23,24). These may limit its use in clinical diagnosis and prognosis.

In conclusion, the upregulation of CTHRC1 in patients with HNSCC is related to the pathological grade, Tumor-Node-Metastasis stage, lymphatic metastasis, HPV status, TP53 mutation and TICs, which may lead to poor prognosis in patients with HNSCC. In addition, upregulation of CTHRC1 may activate tumor and immune related pathways, leading to the infiltration of immune cells and macrophage polarization in the tumor microenvironment in HNSCC. The present study identified a potential role of CTHRC1 in immunology and its adverse prognostic value in HNSCC. CTHRC1 should therefore be considered as a prognostic marker and therapeutic target for HNSCC.

Acknowledgements

Funding

Availability of data and materials

The data used in the present study may be accessed from the TCGA (https://tcga-data.nci.nih.gov/tcga/, head and neck squamous cell carcinoma, the RNA-seq data 'workflow type, HTSeq-FPKM' and relevant clinical data for the 'TCGA-HNSC' cohort), oncomine (https://www.oncomine.org/resource/main.html, Gene, CTHRC1; cut-off P-value, 0.05; cut-off fold change, 1), KM plotter (http://kmplot.com/analysis/, head and neck squamous cell carcinoma, KM plotter contains data and clinical information from the Gene Expression Omnibus, TCGA and European Genome-Phenome Archive databases), UALCAN (http://ualcan.path.uab.edu,

TCGA-head and neck squamous cell carcinoma, contains level 3 RNA-seq data and clinical information from the TCGA database and is an interactive and comprehensive web resource for analyzing cancer omics data) and Timer (https://cistrome.shinyapps.io/timer/, head and neck squamous cell carcinoma, gene expression levels were presented as log2 transcripts per million) databases. The remaining datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

LW and JHZ proposed the idea for and designed the study. RLZ, MLY and RZ completed the data analysis work, RLZ and MLY drew the figures, MLY and LW drafted the manuscript and JHZ reviewed the manuscript. RLZ, MLY and LW confirm the authenticity of all the raw data. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

Human tissue specimens were obtained from patients who provided written informed consent and the present study and tissue collection was approved by the Ethics Supervision Committee of The People's Hospital of Tongxu County (Kaifeng, China; approval no. TX20NP003) and the National Human Genetic Resources Sharing Service Platform (2005DKA21300). The study protocol was approved by the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China; approval no. 2020IEC-J050).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Wyss A, Hashibe M, Chuang SC, Lee YC, Zhang ZF, Yu GP, Winn DM, Wei Q, Talamini R, Szeszenia-Dabrowska N, *et al*: Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: Pooled analysis in the international head and neck cancer epidemiology consortium. Am J Epidemiol 178: 679-690, 2013.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018.
3. Ferris RL: Immunology and immunotherapy of head and neck cancer. J Clin Oncol 33: 3293-3304, 2015.
4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-E386, 2015.
5. Kuss I, Hathaway B, Ferris RL, Gooding W and Whiteside TL: Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10: 3755-3762, 2004.
6. Bauernhofer T, Kuss I, Henderson B, Baum AS and Whiteside TL: Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol 33: 119-124, 2003.
7. Ferris RL: Progress in head and neck cancer immunotherapy: Can tolerance and immune suppression be reversed? ORL J Otorhinolaryngol Relat Spec 66: 332-340, 2004.
8. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, *et al*: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet 394: 1915-1928, 2019.
9. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, *et al*: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. New Engl J Med 375: 1856-1867, 2016.
10. Pyagay P, Heroult M, Wang Q, Lehnert W, Belden J, Liaw L, Friesel RE and Lindner V: Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res 96: 261-268, 2005.
11. Duan X, Yuan X, Yao B, Song W, Li Z, Enhejirigala, Kong Y, Wang Y, Fu X and Huang S: The role of CTHRC1 in promotion of cutaneous wound healing. Signal Transduct Target Ther 7: 183, 2022.
12. Bian Z, Miao Q, Zhong W, Zhang H, Wang Q, Peng Y, Chen X, Guo C, Shen L, Yang F, *et al*: Treatment of cholestatic fibrosis by altering gene expression of Cthrc1: Implications for autoimmune and non-autoimmune liver disease. J Autoimmun 63: 76-87, 2015.
13. Takeshita S, Fumoto T, Matsuoka K, Park KA, Aburatani H, Kato S, Ito M and Ikeda K: Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. J Clin Invest 123: 3914-3924, 2013.
14. Stohn JP, Wang Q, Siviski ME, Kennedy K, Jin YR, Kacer D, DeMambro V, Liaw L, Vary CP, Rosen CJ, *et al*: Cthrc1 controls adipose tissue formation, body composition, and physical activity. Obesity (Silver Spring) 23: 1633-1642, 2015.
15. Ni SJ, Ren F, Xu M, Tan C, Weng W, Huang Z, Sheng W and Huang D: CTHRC1 overexpression predicts poor survival and enhances epithelial-mesenchymal transition in colorectal cancer. Cancer Med 7: 5643-5654, 2018.
16. Ding X, Huang R, Zhong Y, Cui N, Wang Y, Weng J, Chen L and Zang M: CTHRC1 promotes gastric cancer metastasis via HIF-1α/CXCR4 signaling pathway. Biomed Pharmacother 123: 109742, 2020.
17. Yan L, Yu J, Tan F, Ye GT, Shen ZY, Liu H, Zhang Y, Wang JF, Zhu XJ and Li GX: SP1-mediated microRNA-520d-5p suppresses tumor growth and metastasis in colorectal cancer by targeting CTHRC1. Am J Cancer Res 5: 1447-1459, 2015.
18. Ma MZ, Zhuang C, Yang XM, Zhang ZZ, Ma H, Zhang WM, You H, Qin W, Gu J, Yang S, *et al*: CTHRC1 acts as a prognostic factor and promotes invasiveness of gastrointestinal stromal tumors by activating Wnt/PCP-Rho signaling. Neoplasia 16: 265-278, 278.e1-e13, 2014.
19. Hou MZ, Cheng ZQ, Shen HW, He S, Li Y, Pan Y, Feng C, Chen X, Zhang Y, Lin M, *et al*: High expression of CTHRC1 promotes EMT of epithelial ovarian cancer (EOC) and is associated with poor prognosis. Oncotarget 6: 35813-35829, 2015.
20. Wang C, Li Z, Shao F, Yang X, Feng X, Shi S, Gao Y and He J: High expression of collagen triple helix repeat containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation. J Exp Clin Canc Res 36: 84, 2017.
21. Zheng M, Zhou Q, Liu X, Wang C and Liu G: CTHRC1 overexpression promotes cervical carcinoma progression by activating the Wnt/PCP signaling pathway. Oncol Rep 41: 1531-1538, 2019.
22. Yuan RX, Bao D and Zhang Y: Linc00707 promotes cell proliferation, invasion, and migration via the miR-30c/CTHRC1 regulatory loop in breast cancer. Eur Rev Med Pharmaco 24: 4863-4872, 2020.
23. Zhou H, Su L, Liu C, Li B, Li H, Xie Y and Sun D: CTHRC1 may serve as a prognostic biomarker for hepatocellular carcinoma. Onco Targets Ther 12: 7823-7831, 2019.
24. Sial N, Ahmad M, Hussain MS, Iqbal MJ, Hameed Y, Khan M, Abbas M, Asif R, Rehman JU, Atif M, *et al*: CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes. Sci Rep 11: 19873, 2021.
25. Bai Y, Yin K, Su T, Ji F and Zhang S: CTHRC1 in ovarian cancer promotes M2-like polarization of tumor-associated macrophages via regulation of the STAT6 signaling pathway. Onco Targets Ther 13: 5743-5753, 2020.

26. Wang Z, Jensen MA and Zenklusen JC: A practical guide to the cancer genome atlas (TCGA). Methods Mol Biol 1418: 111-141, 2016.
27. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9: 166-180, 2007.
28. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res 77: e108-e110, 2017.
29. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19: 649-658, 2017.
30. Reis-Filho JS and Tutt ANJ: Triple negative tumours: A critical review. Histopathology 52: 108-118, 2008.
31. Shien T, Shimizu C, Seki K, Shibata T, Hojo T, Ando M, Kohno T, Katsumata N, Akashi-Tanaka S, Kinoshita T and Fujiwara Y: Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome. Breast Cancer Res Treat 113: 307-313, 2008.
32. Lánczky A and Győrffy B: Web-based survival analysis tool tailored for medical research (KMplot): Development and implementation. J Med Internet Res 23: e27633, 2021.
33. Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin 72: 7-33, 2022.
34. Lee CE, Vincent-Chong VK, Ramanathan A, Kallarakkal TG, Karen-Ng LP, Ghani WM, Rahman ZA, Ismail SM, Abraham MT, Tay KK, et al: Collagen triple helix repeat containing-1 (CTHRC1) expression in oral squamous cell carcinoma (OSCC): Prognostic value and clinico-pathological implications. Int J Med Sci 12: 937-945, 2015.
35. Liu GL, Sengupta PK, Jamal B, Yang HY, Bouchie MP, Lindner V, Varelas X and Kukuruzinska MA: N-glycosylation induces the CTHRC1 protein and drives oral cancer cell migration. J Biol Chem 288: 20217-20227, 2013.
36. Scheel C, Eaton EN, Li SHJ, Chaffer CL, Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL and Weinberg RA: Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145: 926-940, 2011.
37. Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, et al: The KRAS-variant and cetuximab response in head and neck squamous cell cancer: A secondary analysis of a randomized clinical trial. JAMA Oncol 3: 483-491, 2017.
38. Loganathan SK, Schleicher K, Malik A, Quevedo R, Langille E, Teng K, Oh RH, Rathod B, Tsai R, Samavarchi-Tehrani P, et al: Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling. Science 367: 1264-1269, 2020.
39. Oshimori N, Oristian D and Fuchs E: TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 160: 963-976, 2015.
40. Guo B, Yan H, Li L, Yin K, Ji F and Zhang S: Collagen triple helix repeat containing 1 (CTHRC1) activates Integrin β3/FAK signaling and promotes metastasis in ovarian cancer. J Ovarian Res 10: 69, 2017.